SARS-CoV-2 Mpro Inhibitor Compounds for Coronaviral Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments for coronaviral-related diseases, particularly COVID-19, as existing inhibitors for SARS-CoV-2 main protease (Mpro) are limited in efficacy and availability.
Innovation Solution
Development of a compound of Formula (I) and its stereoisomers or pharmaceutically acceptable salts, which act as inhibitors of SARS-CoV-2 main protease, formulated into pharmaceutical compositions for treatment, management, or prevention of coronaviral-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Mpro inhibitors are used for treatment, then some antiviral effect is achieved, but efficacy is limited and availability is restricted
Solution Approach 1:
The patent modifies the chemical structure parameters of existing Mpro inhibitors by introducing different substituents (R1, R2, X1, X2 groups) at specific positions of the core scaffold, creating a series of analogs with improved efficacy and broader availability for treating coronaviral diseases
Solution Approach 2:
The developed compounds are designed to inhibit Mpro across multiple coronavirus types (SARS-CoV, SARS-CoV-2, MERS-CoV), providing a universal therapeutic agent that addresses both the efficacy limitation and availability restriction by being effective against various coronaviruses
2Reliability
If peptidomimetic inhibitors are used, then Mpro inhibition is achieved, but structural complexity increases
Solution Approach 1:
The patent introduces specific functional groups (X1, X2) at localized positions of the peptidomimetic scaffold, allowing Mpro inhibition through targeted molecular interactions while maintaining relative structural simplicity in other regions of the molecule
Solution Approach 2:
The compounds feature asymmetric substitution patterns with specific R1 and R2 groups at defined positions, creating chiral centers that enhance Mpro binding affinity and selectivity while managing structural complexity through deliberate asymmetric design rather than random complexity
3Device complexity
If non-peptidic small molecule inhibitors are used, then structural simplicity is maintained, but antiviral effectiveness is reduced
Solution Approach 1:
The patent creates hybrid peptidomimetic structures that combine peptide-like functional groups (for high Mpro affinity) with non-peptide scaffolds (for structural simplicity and oral bioavailability), achieving both antiviral effectiveness and manageable structural complexity in a single molecule
Data Source
AI summary
Provided herein are compounds and compositions for treating, managing or preventing coronaviral related diseases. In particular, provided herein are compounds which are inhibitors of SARS-CoV-2 main protease (Mpro), pharmaceutical compositions comprising such compounds, method for synthesizing such compounds and methods of using such compounds and compositions for the treatment, management or prevention of coronaviral related diseases.